• Indications
  • Open Access TIMES Journals
Login Register
Login Register
Indications
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Open Access TIMES Journals
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Oncology · Hematology

Oncology · Hematology

Case Reports
Expert Opinions
Congress News
E-Learning
Webinar
Faculty
healthbook TIMES
Homepage >
Oncology · Hematology >
Articles

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma

Lymphoma
Share:
Do you want to read an article? Please log in or register.
Register for Free
Remember me
Forgot password? Click here

Related content

Lymphoma
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network)
Leuk Lymphoma
Cencini E, Palazzo M, Dardanis D, Lucco Navei G, Mannelli L, Zoi V, Mecacci B, Sordi B, Cervetti G, Rosati S, Nassi L, Bocchia M, Fabbri A
doi: 10.1080/10428194.2025.2456094
EHA 2024
Lymphoma
BrECADD regimen is superior in treating advanced Hodgkin lymphoma with improved patient outcomes
Lymphoma
Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study
Leukemia
Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, Maruyama D, Kubota N, Maeda T, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Taguchi S, Asano N, Yamaguchi M, Suzuki R
doi: 10.1038/s41375-025-02527-4
Lymphoma
PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study
Leuk Lymphoma
Jin J, Meng DD, Wen Y, Zhang QL, Lv FF, Chen GL, Ma XJ, Yu BH, Zhang SJ, Liu C, Xia ZG
doi: 10.1080/10428194.2024.2447888
Lymphoma
Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVD(DD-DI) phase II study
Br J Haematol
Corazzelli G, Cuccaro A, Morelli E, Arcamone M, De Chiara A, Paccone A, Petrillo A, Ibello F, Aversa C, Esposito M, Volzone F, Saggese M, Capobianco G, Sarno S, Sirica L, Crisci S, De Filippi R, Pinto A
doi: 10.1111/bjh.19646
Lymphoma
Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma
Leuk Lymphoma
Frey C, Etminan M
doi: 10.1080/10428194.2025.2461663
Lymphoma
Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases
Br J Haematol
Kim JL, Villa D, Tonseth RP, Gerrie AS, Wilson D, Benard F, Venner CP, Skinnider B, Farinha P, Slack GW, Lo AC, Scott DW, Sehn LH, Savage KJ
doi: 10.1111/bjh.19859
ESMO 2024
Skin Cancer
CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma
Skin Cancer
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
J Clin Oncol
Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS
doi: 10.1200/JCO.24.00400
  • Contact us
  • About us
  • Privacy Policy & Disclaimer
  • Online Media 2025 Data
  • Imprint
healthbook is a registered trademark. Copyright © 2025 healthbook